Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Atlas of clinical PET-CT in treatment response evaluation in oncology / / Stefano Fanti, Gopinath Gnanasegaran, Ignasi Carrió, editors
| Atlas of clinical PET-CT in treatment response evaluation in oncology / / Stefano Fanti, Gopinath Gnanasegaran, Ignasi Carrió, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (483 pages) |
| Disciplina | 616.99407575 |
| Soggetto topico |
Cancer - Tomography
Quimioteràpia del càncer Radioteràpia Tomografia per emissió de positrons |
| Soggetto genere / forma |
Llibres electrònics
Atles (Científic) |
| ISBN | 3-030-68858-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- List of Contributors -- Part I: Therapy Response Evaluation: Science and Practice -- 1: Treatment Response Evaluation: Science and Practice -- 1.1 Introduction -- 1.2 Criteria for Evaluating Response -- 1.3 Traditional Response Criteria -- 1.4 Incorporation of Molecular Imaging into Response Criteria -- 1.5 Response Criteria and Immunotherapy -- 1.6 Practical Considerations -- References -- 2: CT in Treatment Response Assessment in Oncology -- 2.1 Introduction -- 2.2 Current Response Assessment Criteria for Chemotherapy and Targeted Therapies -- 2.3 Pitfalls of RECIST 1.1 -- 2.4 mRECIST in HCC -- 2.5 Lugano Classification in Lymphoma -- 2.6 Response Assessment Criteria in Immunotherapy -- 2.7 Conclusion -- References -- 3: MRI and Diffusion-Weighted MRI in Treatment Response Evaluation Overview -- 3.1 Introduction -- 3.2 Response Evaluation by Tumour Burden or Anatomical Parameters -- 3.2.1 WHO and RECIST Criteria -- 3.2.2 iRECIST -- 3.2.3 Other Response Evaluation by Anatomical MRI in Specific Disease Contexts -- 3.2.3.1 Brain Tumour -- 3.2.3.2 Hepatocellular Carcinoma (HCC) -- 3.2.3.3 Rectal Cancer -- 3.3 Response Evaluation with Diffusion-Weighted Imaging (DWI) -- 3.4 Conclusion -- References -- 4: PET and PET-CT in Treatment Response Evaluation: Overview -- 4.1 Introduction: Why Is Tumor Response Assessed by Imaging? -- 4.2 Assessment of Tumor Response: When and How? -- 4.2.1 Response Assessment by FDG PET -- 4.2.1.1 Response Assessment in Lymphoma -- 4.2.2 Response Assessment with Other PET Imaging Agents -- 4.2.3 Timing of Response Assessment -- 4.3 Responders vs. Nonresponders -- 4.4 Management and Type of Treatment -- 4.5 Common Patterns, Pitfalls, Variants, Advantages, and Limitations -- 4.5.1 Standardized Imaging Protocol -- 4.5.2 Impact of Therapy on FDG Metabolism.
4.5.3 Radiation Therapy -- 4.5.4 Immunotherapy -- 4.5.5 Clinical Image Interpretation -- References -- 5: Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Postsurgical Setting -- 5.1 Introduction -- 5.2 Computed Tomography (CT) -- 5.3 Magnetic Resonance Imaging (MRI) -- 5.4 Positron Emission Tomography (PET) -- 5.5 Other Radiotracers (Neuroendocrine Tumors, Prostate Cancer) -- 5.6 Conclusion -- References -- 6: Conventional Radiological and PET-CT Assessment of Treatment Response Evaluation in Chemotherapy Setting -- 6.1 Introduction -- 6.2 Conventional Radiological Techniques -- 6.3 PET/CT in Response Assessment to Chemotherapy -- 6.3.1 EORTC -- 6.3.2 IHP Criteria for Lymphoma -- 6.3.3 Deauville Criteria for Lymphoma -- 6.3.4 PERCIST -- 6.4 MRI and CT in Response Assessment to Chemotherapy -- 6.5 Evaluation of Response to Chemotherapy in Individual Tumours -- 6.5.1 Oesophageal and Gastric Cancer -- 6.5.2 Colorectal Cancer -- 6.5.3 Hepatocellular Carcinoma -- 6.5.4 Pancreatic Cancer -- 6.5.5 Lung Cancer -- 6.5.6 Lymphoma -- 6.5.7 Head and Neck Cancer -- 6.5.8 Breast Cancer -- 6.5.9 Other Tumours -- 6.6 Conclusion -- References -- 7: Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Post-Radiotherapy Setting -- 7.1 Introduction -- 7.2 Functional Imaging for Disease Response Assessment to Radiotherapy -- 7.2.1 Functional, Metabolic PET Imaging -- 7.2.1.1 Glucose Metabolism -- 7.2.1.2 Tumor Hypoxia -- 7.2.1.3 Tumor Cell Proliferation -- 7.2.1.4 Apoptosis -- 7.2.1.5 Amino Acid Transport and Protein Synthesis -- 7.2.1.6 Cell Membrane Synthesis -- 7.2.1.7 Epidermal Growth Factor Receptor Status -- 7.2.2 Functional MR Imaging Techniques -- 7.2.2.1 Dynamic Contrast-Enhanced MR Imaging -- 7.2.2.2 Diffusion-Weighted MR Imaging -- 7.2.2.3 BOLD Imaging. 7.2.2.4 MR Spectroscopy -- 7.2.3 Functional Imaging with Perfusion CT -- 7.2.4 Emerging Integrated Hybrid Imaging Techniques -- 7.2.4.1 Integrated PET/CT Perfusion Imaging -- 7.2.4.2 Integrated PET-MR Imaging -- 7.3 Assessment of Treatment Response After Radiotherapy -- 7.3.1 Anatomic Response Criteria (WHO, RECIST) -- 7.3.1.1 WHO Criteria -- 7.3.1.2 RECIST v1.1 -- 7.3.1.3 Limitations of Anatomic Response Criteria -- 7.3.2 Metabolic Response Criteria -- 7.3.2.1 Qualitative Assessment -- 7.3.2.2 Quantitative Assessment (PERCIST v1.0) -- 7.4 Current Uses of FDG PET/CT in Treatment Response Following Radiation Therapy -- 7.4.1 Head and Neck Cancer -- 7.4.2 Esophageal Carcinoma -- 7.4.3 Rectal Carcinoma -- 7.4.4 Brain Tumors -- 7.4.5 Cervical Carcinoma -- 7.4.6 Lung Carcinoma -- 7.4.7 Hepato-Pancreatico-Biliary Tumors, Particularly Pancreatic Carcinoma and Liver Metastases (Postselective Internal Radiotherapy Treatment) -- References -- 8: Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings -- 8.1 Introduction -- 8.2 Management: Type of Treatments/Regimes -- 8.2.1 Melanoma -- 8.2.2 NSCLC -- 8.2.3 Other Solid Tumors -- 8.3 Pathophysiology -- 8.4 Assessment of Treatment Response -- 8.4.1 Anatomic Response Assessment -- 8.4.2 Metabolic Response Criteria -- 8.4.3 Responders Vs. Non-Responders -- 8.4.4 Pitfalls and beyond (Pseudo-, Hyper-Progression, irAEs, Brain Mets, Cost-Effectiveness) -- References -- 9: Treatment Response Evaluation of Bone Metastases Using 18F-NaF -- 9.1 Introduction -- 9.2 Management and Types of Treatments -- 9.2.1 Baseline 18F-Fluoride PET/CT -- 9.2.1.1 Prostate Cancer -- 9.2.1.2 Breast Cancer -- 9.2.1.3 Lung Cancer -- 9.2.1.4 Thyroid Cancer -- 9.2.1.5 Renal Cell Cancer. 9.3 Assessment of Treatment Response (Postsurgical, Post Chemotherapy, Post Radiotherapy, Neoadjuvant, and Immunotherapy Settings) -- 9.3.1 Interim 18F-Fluoride PET/CT -- 9.3.1.1 Prostate Cancer -- 9.3.1.2 Breast Cancer -- 9.3.2 Follow-Up 18F-Fluoride PET/CT -- 9.3.2.1 Prostate Cancer -- 9.3.2.2 Breast Cancer -- 9.3.2.3 Multiple Myeloma -- 9.3.2.4 Metastatic Primary Bone Tumors -- 9.3.3 Conclusions -- 9.4 Common Patterns, Pitfalls, Variants, Advantages, and Limitations -- References -- 10: Reporting Post-Therapy Scans -- 10.1 Introduction -- 10.2 Patient Preparation -- 10.3 Clinical Details -- 10.4 Questions to Ask Patient -- 10.5 When to Scan -- 10.6 What to Look for in the Scans -- 10.7 How to Describe, Report Post-Therapy Finding Scores, Criteria, etc. (Post-Surgical, Post-Chemotherapy, Post-Radiotherapy, and Post-Immunotherapy Settings) -- 10.8 Common and Less Common Findings -- 10.9 How to Interpret the Findings: Dos and Don'ts -- 10.9.1 What to Do -- 10.9.2 What Not to Do -- 10.10 What to Advise the Referrers -- References -- Part II: Therapy Response Evaluation: Clinical Atlas -- 11: 18F-FDG PET/CT in Treatment Response Evaluation in Head and Neck Cancer -- 11.1 Case 1 -- 11.2 Case 2 -- 11.3 Case 3 -- 11.4 Case 4 -- 11.5 Case 5 -- 11.6 Case 6 -- 11.7 Case 7 -- 11.8 Case 8 -- 11.9 Case 9 -- 11.10 Case 10 -- 11.11 Case 11 -- 11.12 Case 12 -- 11.13 Case 13 -- 11.14 Case 14 -- 11.15 Case 15 -- Suggested Reading -- Case 3 -- 12: PET/CT in Treatment Response Evaluation: Lung Cancer -- 12.1 Introduction -- References -- 13: 18F-FDG PET/CT and Non 18F-FDG-PET/CT in Treatment Response Evaluation in Neuro-Oncology -- 13.1 Introduction -- 13.2 PET Tracers Used in Neuro-Oncology -- 13.3 Case 1 -- 13.4 Case 2 -- 13.5 Case 3 -- 13.6 Case 4 -- 13.7 Case 5 -- 13.8 Case 6 -- 13.9 Case 7 -- 13.10 Case 8. 13.11 Case 9 -- 13.12 Case 10 -- 13.13 Case 11 -- 13.14 Case 12 -- 13.15 Case 13 -- 13.16 Case 14 -- 13.17 Case 15 -- References -- 14: PET/CT in the Assessment of Treatment Response in Hepatobiliary, Gall Bladder and Pancreatic Malignancies -- 14.1 Introduction -- 14.2 Case 1 -- 14.3 Case 2 -- 14.4 Case 3 -- 14.5 Case 4 -- 14.6 Case 5 -- 14.7 Case 6 -- 14.8 Case 7 -- 14.9 Case 8 -- 14.10 Case 9 -- 14.11 Case 10 -- 14.12 Case 11 -- 14.13 Case 12 -- 14.14 Case 13 -- 14.15 Case 14 -- 14.16 Case 15 -- 14.17 Case 16 -- 14.18 Case 17 -- 14.19 Case 18 -- Suggested Reading -- Introduction -- Case 1 -- Case 2 -- Case 3 -- Case 4 -- Case 6 -- Case 7 -- Case 8 -- Case 11 -- 15: 18F-FDG PET/CT in Treatment Response Evaluation: Gastroesophageal Cancer -- 15.1 Introduction -- 15.2 Case No. 1: Radiation-Induced Esophagitis -- 15.3 Case No. 2: Radiation-Induced Pneumonitis -- 15.4 Case No. 3: Post Transthoracic Esophagectomy (TTE) Appearance -- 15.5 Case No. 4: Aspiration Pneumonia -- 15.6 Case No. 5: Recurrent Aspiration Pneumonia -- 15.7 Case No. 6: Tracheoesophageal Fistula (TOF) -- 15.8 Case No. 7: Upper Esophageal Mass with Complete Response Post CTRT -- 15.9 Case No. 8: Post CTRT Complete Response with Inflammatory Changes in the Esophagus -- 15.10 Case No. 9: Complete Response on PET/CT with Microscopic Residual Disease on Histopathology -- 15.11 Case No. 10: Posttreatment Changes Vs. Residual Disease -- 15.12 Case No. 11: Partial Response to Treatment -- 15.13 Case No. 12: Stable Disease with Radiation-Induced Esophagitis -- 15.14 Case No. 13: GE Junction Mass with Partial Response -- 15.15 Case No. 14: Complete Response -- 15.16 Case No. 15: Coexisting Malignancy and Granulomatous Infection -- 15.17 Case No. 16: Esophageal Primary with Coexisting Tuberculous Infection in the Lungs. 15.18 Case No. 17: GE Junction and Proximal Stomach Mass with Partial Response. |
| Record Nr. | UNINA-9910491028203321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Nuclear oncology : from pathophysiology to clinical applications / / Duccio Volterrani [and four others], editors
| Nuclear oncology : from pathophysiology to clinical applications / / Duccio Volterrani [and four others], editors |
| Edizione | [Third edition.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (2241 pages) |
| Disciplina | 616.99407575 |
| Soggetto topico |
Cancer - Radionuclide imaging
Cancer - Radiotherapy Nuclear medicine |
| ISBN | 3-031-05494-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface to the Third Edition -- Preface to the Second Edition -- Preface to the First Edition -- Acknowledgments -- Contents -- About the Editors -- Contributors -- Part I: Basic Science -- 1 Cancer Biology of Molecular Imaging -- Introduction -- The Evolving Context of Molecular Imaging: Cancer Genomics and Epigenomics -- Hallmarks of Cancer -- The Tumor Mass -- Imaging the Tumor Mass -- Neovasculature -- Hypoxia -- Cellular Constituents and Cell-Cell Synergism of the Tumor Mass -- Immune Cell Cancer Immunotherapy -- Immune Checkpoint Blockade -- Imaging the Immune T Cells -- The Metastatic Process -- Imaging the Cancer Cell -- Total Lesion Glycolysis (TLG) as a Predictive Marker of Prognosis and Tumor Responsiveness -- Proliferation Imaging -- 18F-FLT Imaging of Proliferation After Chemotherapy -- The Cancer Biology of Cellular Lineage Plasticity and the Nuclear Imaging Phenotype -- Lineage Plasticity and Relevance to Molecular Imaging in Prostate Cancer -- Molecular Imaging of Fibroblast-Activating Protein, a Molecule Expressed in Tumor Stroma -- Oncogene and Non-oncogene Addiction -- Examples of Imaging the Action Driver Mutations in Cancer Cells Indirectly Through the Effects on Metabolism -- BRAF Inhibition in Advanced Melanoma with V600E Mutation -- Inhibition of MEK, a Downstream Signal Transduction Molecule in the RAS/BRAF/ERK Pathway, Can Reverse 131I Resistance in Patie... -- Future Applications -- References -- 2 Principles of Molecular Targeting for Radionuclide Therapy -- Introduction -- The Choice of Radionuclide -- Nuclear Properties -- Radioisotope Production -- Theranostics -- Instrument Resolution and Biological Resolution -- Radiobiological Properties Affecting the Choice of Radionuclide -- Radiation Microdosimetry and Particle Range -- The Choice of a Chemical Platform -- Salts and Covalent Bonds -- Chelating Agents.
Coordination of Tc(V) and Re(V) -- Nanoparticles -- Location of the Target: The Challenges of Designing Radiotracers for Intracellular Compartments -- Critical Subcellular Sites of Interaction with Ionizing Radiation (Direct Effects) -- Radiation-Induced Biological Bystander Effects (RIBBEs) -- Critical Subcellular Sites of Interaction with Ionizing Radiation (Indirect Effects) -- Cell Membrane -- Mitochondria -- Transfectant Mosaic Spheroid Model -- Transfectant Mosaic Xenograft Model -- Media Transfer -- LET and Dose Rate -- Conclusion -- References -- 3 Single-Photon Emitting Radiopharmaceuticals for Diagnostic Applications -- Introduction -- 99mTc-Labeled Radiopharmaceuticals -- 99mTc-Sodium Pertechnetate -- 99mTc-Diphosphonates -- 99mTc-Radiocolloids -- 99mTc-Magroaggregated Albumin -- 99mTc-Sestamibi -- 99mTc-Tetrofosmin -- 99mTc-EDDA/HYNIC-Octreotide or Octreotate -- Lung Ventilation Radiopharmaceuticals -- 99mTc-DTPA -- 99mTc-Technegas -- Xenon-133 -- Xenon-127 -- Radioiodinated Agents -- Sodium Iodide -- Radioiodinated Metaiodobenzylguanidine -- 201Tl-Chloride -- 111In-Pentetreotide -- 111In-Capromab Pendetide -- 67Ga-Citrate -- Suggested Readings -- 4 Positron-Emitting Radiopharmaceuticals for Diagnostic Applications in Oncology -- Introduction -- Positron-Emitting Radionuclides -- Carbon-11 (11C) -- Nitrogen-13 (13N) -- Oxygen-15 (15O) -- Fluorine-18 (18F) -- Copper-64 (64Cu) -- Gallium-68 (68Ga) -- Rubidium-82 (82Rb) -- PET Radiopharmaceuticals -- Deoxy-[18F]fluoro-d-glucose -- Nitrogen-13 Ammonia -- Oxygen-15 Water -- Rubidium-82 Chloride -- [11C]Methionine and Other Tracers for Protein Synthesis -- Choline-Based Tracers for Phospholipid Synthesis -- Fluorine-18 Fluciclovine -- Gallium-68 PSMA Ligands -- Fluorine-18 Sodium Fluoride -- Fluorine-18 Misonidazole and Other Hypoxia Tracers. Fluorine-18 Fluorothymidine and Other Substrates for DNA Synthesis -- Fluorine-18 DOPA and Other Amine Precursors -- Gallium-68 DOTATOC, Copper-64 DOTATATE, and Other Somatostatin Analogs -- Suggested Readings -- 5 Radiopharmaceuticals for Therapy -- Background -- Alpha-Particle Emitters -- Radium-223 (223Ra) -- Auger Electron Emitters -- Emitters of β- Particles -- Iodine-131 (131I) -- Yttrium-90 (90Y) -- Lutetium-177 (177Lu) -- Samarium-153 (153Sm) -- Strontium-89 (89Sr) -- Rhenium-186 (186Re) and Rhenium-188 (188Re) -- Phosphorus-32 (32P) -- Holmium-166 (166Ho) -- Treatment of Thyroid Disease with 131I-Iodide -- Treatment of Neuroendocrine Neoplasms Originating from the Neural Crest with [131I]MIBG -- Peptide Receptor Radionuclide Therapy -- Bone-Seeking Radiopharmaceuticals and Prostate Cancer -- Radioimmunotherapy for Hematologic Malignancies -- Radionuclide Therapy of Primary and Metastatic Liver Tumors -- Suggested Readings -- 6 Novel Single-Photon-Emitting Radiopharmaceuticals for Diagnostic Applications -- Introduction and Background -- Peptide Receptor Targeting -- 99mTc-EDDA/HYNIC-TOC -- 99mTc-PSMA-Ligands -- 99mTc-CAIX -- Apoptosis -- 99mTc-Annexin V -- 99mTc-Duramycin -- Angiogenesis -- 99mTc-HYNIC-VEGF -- Integrins -- 99mTc-αP2 -- 99mTc-NC100692 (or 99mTc-Maraciclatide) -- 99mTc-3PRGD2 -- 99mTc-RGD-BBN -- Hybrid Radioactive/Fluorescent RGD -- Agents Targeting the Extracellular Matrix -- 99mTc-AP39 -- Matrix Metalloproteinases -- Epidermal Growth Factor Receptor (EGFR) -- 99mTc-ADAPT6 -- Folate Receptor Overexpression -- 99mTc-HYNIC-folate -- References -- 7 Novel Positron-Emitting Radiopharmaceuticals -- Introduction -- Targeting Cellular Transport and Metabolism -- Overview -- Imaging Amino Acid Transport and Metabolism -- [11C]Methionine -- O-(2-[18F]Fluoroethyl)-L-Tyrosine ([18F]FET). 3,4-Dihydroxy-6-[18F]Fluorophenylalanine ([18F]FDOPA) -- 18F-Labeled Glutamine -- Imaging Lipid Biosynthesis -- Targeting Cell Surface Receptors -- Overview -- Imaging the Expression of Integrins -- Imaging the Expression of Gastrin-Releasing Peptide Receptors -- ImmunoPET Imaging -- ImmunoPET of HER2 -- ImmunoPET of EGFR -- ImmunoPET of PD-1/PD-L1 -- Targeting the Tumor Microenvironment -- Overview -- Imaging Tumor Hypoxia -- Imaging Tumor Acidosis -- Radiotheranostics -- Overview -- Targeting Somatostatin Receptors -- Targeting Prostate-Specific Membrane Antigen -- Radioimmunotherapy -- Concluding Remarks -- References -- 8 Novel Radiopharmaceuticals for Therapy -- Introduction -- Alpha-Emitting Agents -- Radium-223 (223Ra) -- Astatine-211 (211At) -- Actinium-225 (225Ac) -- Thorium-227 (227Th) -- Bismuth-213 (213Bi) -- Lead-212 (212Pb) -- Agents Emitting β- Particles -- Iodine-131 (131I) -- Lutetium-177 (177Lu) -- Holmium-166 (166Ho) -- Ytterbium-175 (175Yb) -- Samarium-153 (153Sm) -- Thulium-170 (170Tm) -- Copper-67 (67Cu) -- Yttrium-90 (90Y) -- Gold-198 (198Au) -- Promethium-149 (149Pm) -- Rhodium-105 (105Rh) -- Other Radionuclides -- Concluding Remarks -- References -- 9 Physics of Nuclear Oncology -- Structure of the Atom -- Energy and Mass -- Energy and Frequency -- Energy and Mass -- Radioactivity and Radiation -- Electromagnetic Radiation -- X-Rays -- Gamma Radiation (γ) -- Annihilation Radiation (γ±) -- Particulate Radiations -- Alpha Radiation (α) -- Beta Radiation (β-) -- β- Dosimetry -- Positron Decay (β+) and Electron Capture (EC) -- Auger Electrons -- Isomeric Transition (IT) and Internal Conversion (IC) -- Radioactive Decay -- Interaction of Radiation with Matter -- Interaction of Particulate Radiation with Matter -- Interaction of Photons with Matter -- Photoelectric Effect -- Compton Scattering -- Pair Production. Attenuation and Scattering of Photons -- Photon Attenuation -- Radionuclides Used in Nuclear Oncology -- References -- 10 Instrumentation for Positron Emission Tomography -- Introduction -- Basic Physics and Technology of PET -- Scintillation Crystals -- Silicon Photomultiplier (SiPM)-Based Scintillation Detectors -- Time-of-Flight (TOF) PET -- Total-Body PET -- PET/MRI -- Concluding Remarks -- References -- 11 Instrumentation for Single-Photon Emission Computed Tomography (SPECT) -- Introduction -- Radiation Detectors for SPECT -- Radionuclides for SPECT -- Gamma Camera Design -- SPECT Data-Acquisition -- Data ``Corrections´´ and Activity Quantitation -- Image Reconstruction -- Commercial Devices -- Concluding Remarks -- References -- 12 Instrumentation for Intraoperative Detection and Imaging -- Introduction -- Nuclear Counting and Imaging -- Optical and Near-Infrared (NIR) Imaging -- Cerenkov Imaging -- Photoacoustic Imaging -- Diffuse Optical Tomography -- Optical Coherence Tomography -- Raman Spectroscopic Imaging -- Intraoperative US, CT, and MRI -- Concluding Remarks -- References -- 13 Radiobiology and Radiation Dosimetry in Nuclear Medicine -- Introduction -- Radiobiology -- Conventional Radiobiological Models -- Cell Death Mechanisms -- Possible Contributing Mechanisms to RNT Tumor Responses -- Low-Dose/Dose-Rate Apoptosis -- Low-Dose Hyper-radiosensitivity-Increased Radioresistance -- G2 Synchronization, Bystander, and Cross-Fire Effects -- Adaptive Responses -- Fractionated RNT and Hypoxia -- Future Directions -- Dosimetry: Overview on Methods -- Clinical Experience -- 131I-Iodide Therapy of Differentiated Thyroid Carcinoma -- Peptide Receptor Radionuclide Therapy -- Radioimmunotherapy of Lymphoma -- Dosimetry in the Radioembolization of Liver Tumors -- Therapy of Neuroectodermal Neuroendocrine Malignancies. Treatment of Metastatic Bone Pain. |
| Record Nr. | UNINA-9910616204703321 |
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Nuclear Oncology : From Pathophysiology to Clinical Applications / / edited by H. William Strauss, Giuliano Mariani, Duccio Volterrani, Steven M. Larson
| Nuclear Oncology : From Pathophysiology to Clinical Applications / / edited by H. William Strauss, Giuliano Mariani, Duccio Volterrani, Steven M. Larson |
| Edizione | [2nd ed. 2017.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017 |
| Descrizione fisica | 1 online resource (992 illus., 782 illus. in color. eReference.) |
| Disciplina | 616.99407575 |
| Soggetto topico |
Nuclear medicine
Oncology Nuclear Medicine Oncology |
| ISBN | 3-319-26236-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part I: Basic Science -- Cancer Biology -- Molecular Targeting for Radionuclide Therapy -- Single-photon Emitting Radiopharmaceuticals for Diagnostic Applications -- Positron Emitting Radiopharmaceuticals for Diagnostic Applications -- Radiopharmaceuticals for Therapy -- Novel Single-photon Emitting Radiopharmaceuticalsfor Diagnostic Applications -- Novel Positron Emitting Radiopharmaceuticals -- Novel Radiopharmaceuticals for Therapy -- Physics of Nuclear Oncology -- Instrumentation for Single-photon Emission Imaging -- Instrumentation for Positron Emission Imaging. -Instrumentation for Intraoperative Detection -- Radiobiology and Radiation Dosimetry in Nuclear Medicine -- Part II: Clinical Applications -- Lymphomas: Diagnostic Applications -- Multiple Myeloma -- Leukemias: Diagnostic Applications -- Brain Tumors -- Head and Neck Cancer -- Thyroid Tumors: Diagnostic Applications -- Parathyroid Tumors -- Breast Cancer -- Lung and Mediastinal Tumors -- Esophageal Cancers -- Gastric Cancers -- Small Bowel Cancers -- Tumors of the Liver and Biliary Tract: Diagnostic Applications. - Pancreatic Cancer -- Colorectal Cancer -- Neuroendocrine Tumors: Diagnostic Applications -- Kidney and Bladder Cancer -- Prostatic Cancer -- Testicular Cancer -- Penile Cancer -- Vulvar Cancer -- Uterine Cancers -- Ovarian Cancer -- Sarcomas -- Malignant Melanoma.– Pediatric Cancers: Diagnostic Applications -- Part III: Radionuclide Therapy.– Radionuclide Therapy of Thyroid Tumors -- Radionuclide Therapy of Lymphomas -- Radionuclide Therapy of Leukemias -- Neuroendocrine Tumors: Therapy with Radiolabeled Peptides -- Neuroendocrine Tumors: Therapy with 131I-MIBG -- Targeted Radionuclide Therapy for Bone Metastasis. - Radionuclide Therapy of Tumors of the Liver and Biliary Tract -- Radionuclide Therapy of Pediatric Cancers -- Part IV: Radioguided Surgery -- Radioguided Surgery for Breast Cancer -- Radioguided Surgery for Malignant Melanoma -- Radioguided Surgery: Novel Applications -- Part V: Heart Disease in the Cancer Patient -- Imaging the Heart in the Cancer Patient -- Part VI: Adverse Effects of Cancer Therapy -- Nuclear Medicine in the Assessment of Adverse Effects of Cancer Therapy in the Lung, Kidney, and Gastrointestinal Tract -- Part VII: Teaching Cases -- Lymphomas -- Multiple Myeloma. - Leukemias -- Brain Tumors -- Head and Neck Cancer -- Thyroid Tumors -- Parathyroid Tumors -- Breast Cancer -- Lung and Mediastinal Tumors -- Esophageal Cancers -- Gastric Cancers -- Small Bowel Cancers -- Tumors of the Liver and Biliary Tract. - Pancreatic Cancer -- Colorectal Cancer -- Neuroendocrine Tumors -- Kidney and Bladder Cancer -- Prostatic Cancer -- Testicular Cancer -- Penile Cancer -- Vulvar Cancer -- Uterine Cancers -- Ovarian Cancer. - Sarcomas -- Malignant Melanoma -- Pediatric Cancers -- Radioguided Surgery. |
| Record Nr. | UNINA-9910254496703321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
PET/CT in cancer : an interdisciplinary approach to individualized imaging / / Mohsen Beheshti, Werner Langsteger, Alireza Rezaee ; associate editors, Markus Raderer, Niklaus Schaeffer
| PET/CT in cancer : an interdisciplinary approach to individualized imaging / / Mohsen Beheshti, Werner Langsteger, Alireza Rezaee ; associate editors, Markus Raderer, Niklaus Schaeffer |
| Autore | Beheshti Mohsen |
| Pubbl/distr/stampa | Philadelphia, Pennsylvania : , : Elsevier, , 2017 |
| Descrizione fisica | 1 online resource (262 pages) : illustrations, tables |
| Disciplina | 616.99407575 |
| Soggetto topico | Cancer - Tomography |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Head and neck cancers / Moshen Beheshti, Rathan M. Subramaniam, Alireza Rezaee, Martin Burian, and Werner Langsteger -- Lung cancer / Alireza Rezaee, Ken Hermann, Markus Raderer, Werner Langsteger, and Michael Beheshti -- Breast cancer / Alireza Rezaee, Andreas Buck, Markus Raderer, Werner Langsteger, and Moshen Beheshti -- Gastroesophogeal cancer / Alireza Rezaee, Andreas Buck, Markus Raderer, Werner Langsteger, and Moshen Beheshti -- Gastoenteropancreatic neuroendocrine neoplasms / Moshen Beheshti, Alireza Rezaee, Markus Raderer, and Werner Langsteger -- Colorectal cancer / Moshen Beheshti, Alireza Rezaee, Ken Hermann, Markus Raderer, and Werner Langsteger -- Hepatobiliary cancer / Alireza Rezaee, Rathan M. Subramaniam, Markus Raderer, Werner Langsteger, and Mohsen Beheshti -- Lymphoma / Alireza Rezaee, Heiko Schöder, Markus Raderer, Werner Langsteger, and Mohsen Beheshti -- Gynecological cancers / Alireza Rezaee, Niklaus Schäfer, Norbert Avril, Lukas Hefler, Werner Langsteger, and Mohsen Beheshti -- Prostate cancer / Mohsen Beheshti, Heiko Schöder, Jochen Walz, Alireza Rezaee, and Werner Langsteger -- Melanoma / Alireza Rezaee, Andreas Buck, Niklaus Schäfer, Werner Langsteger, and Mohsen Beheshti -- Brain tumors / Karl-Josef Langen, Alexander Drzezga, and Norbert Galldiks. |
| Record Nr. | UNINA-9910583068403321 |
Beheshti Mohsen
|
||
| Philadelphia, Pennsylvania : , : Elsevier, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Phenotypic Oncology PET : An Instructional Casebook / / by Ching Yee Oliver Wong, Dafang Wu
| Phenotypic Oncology PET : An Instructional Casebook / / by Ching Yee Oliver Wong, Dafang Wu |
| Autore | Wong Ching-Yee Oliver |
| Edizione | [1st ed. 2022.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 |
| Descrizione fisica | 1 online resource (305 pages) |
| Disciplina |
905
616.99407575 |
| Soggetto topico |
Nuclear medicine
Oncology Nuclear Medicine |
| ISBN | 3-031-09737-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Double pulmonary nodules -- Nodular sclerosing Hodgkin’s lymphoma -- Transformation in non-Hodgkin’s lymphoma -- Metabolic phenotypes in different neoplasms -- Marrow involvement in non-Hodgkin’s lymphoma -- Hip pain in lymphoma -- Prostate cancer specific PET agent with rising PSA -- Brain tumor evaluation -- Metabolic phenotypes in slowly growing lung cancers -- Metabolic phenotypes in lung metastasis from colon cancer -- PET and bone scan in non-small cell lung cancer (NSCLC) -- Neuroendocrine cancer of ileum -- Coexisting different PET tumor phenotypes -- COVID vaccination and lung nodules -- COVID vaccination and tumor phenotypes -- Breast and ovarian uptake -- Rising PSA in radical prostatectomy for prostate cancer -- Concurrent lung and brain metastatic cancer -- Tumor phenotypes in metastatic prostate cancer -- Metastatic recurrent melanoma -- Post-prostatectomy for prostate cancer with rising PSA -- Left adrenal mass -- Cutaneous T-cell lymphoma -- Active myeloma versus Schmorl’s node -- Small cell lung cancer -- Synchronous PEComa and lung adenocarcinoma -- Breast cancer after immunochemotherapy -- Squamous cell lung cancer -- Lymphoma and breast cancer -- Prostate cancer -- Neurofibromatosis and cerebellar encephalomalacia -- Mucinous Colonic Adenocarcinoma -- Poorly differentiated gastric cancer with signet-ring cell features -- Granulomatosis disease involving lung, lymph nodes, and multiple bones -- Lung nodules in esophageal cancer -- Squamous cell cancer (SCC) of neck -- Metastatic prostate adenocarcinoma -- Mesothelioma -- Recurrent papillary thyroid carcinoma -- Newly diagnosed prostate adenocarcinoma -- Alveolar rhabdomyosarcoma with a favorable response to chemoradiation -- CNS post-transplant lymphoproliferative disease -- Solitary plasmacytoma -- Parotid oncocytic carcinoma -- Pelvic sarcoma with IVC metastatic thrombus -- Diffuse muscle uptake and vigorous exercise -- Post-excision residual urothelial carcinoma -- Phenotypic pattern of Erdheim-Chester disease (ECD) -- Different metabolic phenotypes in renal clear cell cancer and cervix cancer -- Bladder adenocarcinoma with chemoresistance -- Wax-and-wane metabolic activities of low-grade lymphoma -- Reactive adenopathy in treated classic Hodgkin’s lymphoma -- Chemo-refractory diffuse large B cell lymphoma (DLBCL) -- Primary cutaneous DLBCL, leg type (PC-DLBCL LT) -- Primary pulmonary MALT lymphoma -- Concurrent low-grade follicular lymphoma (LG FL) and DLBCL -- Primary bone lymphoma (PBL) -- Lymphomatoid granulomatosis (LYG) variant of DLBCL -- Secondary central nervous system lymphoma (SCNSL) -- Complete discordant PET in pathologically diagnosed low grade lymphoma -- Transplant-related B-cell lymphoma -- Bone lesions in primary breast lymphoma -- Recurrent gastrointestinal stromal tumor (GIST) with necrosis -- Peritoneal mesothelioma -- Cutaneous Kaposi sarcoma -- FDG-avid and non-FDG-avid multiple myeloma (MM) -- Advanced pancreatic cancer with abdominopelvic carcinomatosis -- Advanced breast cancer with extensive bone metastases -- Concurrent lung cancer and endocervix cancer -- Inflammatory breast cancer -- Recurrent high-grade urothelial carcinoma -- Primary thyroid lymphoma (PTL) -- High-grade tonsillar large B-cell lymphoma -- Phenotypic pattern of primary renal DLBCL with double expressor -- Recurrent primary colonic lymphoma (PCL) -- Maxillofacial extra nodal marginal zone malignant B-cell lymphoma -- Primary dural lymphoma with leptomeningeal involvement -- Primary CNS lymphoma (PCNSL) -- Primary gastric lymphoma -- Residual primary prostate lymphoma -- PET SuperScan -- Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) -- Metastatic ovarian carcinoma -- Metastatic prostate cancer or neuroendocrine tumor? -- Metastatic thyroid carcinoma -- Primary invasive ductal breast cancer or metastatic neuroendocrine cancer? -- Atypical oligo-metastasis of malignant melanoma -- Dual-time PET CT evaluation of lung nodules -- Phenotypic pattern of combined large cell neuroendocrine cancer and SCC -- Primary pulmonary amyloidosis -- Advanced follicular dentritic cell sarcoma -- Oligometastatic prostate cancer -- Bulky primary mediastinal non-Hodgkin’s lymphoma -- Pulmonary sarcoid or recurrent lung adenocarcinoma? -- Oligo- or multiple bone metastases in newly diagnosed prostate cancer -- Reactive lymph nodes and granulomas associated with breast implant rupture -- Metabolic phenotypes of anaplastic thyroid carcinoma and metastases -- Male breast carcinoma -- Advanced HCC featured by IVC/right atrium tumor thrombus -- Phenotypes of lung cancer and pulmonary lymphangitic carcinomatosis. |
| Record Nr. | UNINA-9910619271403321 |
|
Wong Ching-Yee Oliver
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Whole-body FDG PET imaging in oncology : clinical reports / / Pier Francesco Rambaldi ; in collaboration with Giovanni Fontanella
| Whole-body FDG PET imaging in oncology : clinical reports / / Pier Francesco Rambaldi ; in collaboration with Giovanni Fontanella |
| Autore | Rambaldi Pier Francesco |
| Edizione | [1st ed. 2014.] |
| Pubbl/distr/stampa | Milan : , : Springer, , 2014 |
| Descrizione fisica | 1 online resource (xix, 352 pages) : illustrations (some color) |
| Disciplina | 616.99407575 |
| Collana | Gale eBooks |
| Soggetto topico |
Tumors - Radionuclide imaging
Tumors - Tomography Tomography, Emission |
| ISBN | 88-470-5295-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Galbladder and Biliary Ducts -- Head and Neck -- Colon and Rectum -- Oesophagus -- Gynecology -- Lymphomas and Thymomas -- Breast -- Melanoma -- Pancreas -- Lung -- Stomach -- Urinary Tract . |
| Record Nr. | UNINA-9910300331503321 |
|
Rambaldi Pier Francesco
|
||
| Milan : , : Springer, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||